Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the ORION-1 data recently presented at the 2017 American College of Cardiology Conference.

Ticker(s): MDCO, AMGN, REGN, ALNY, SNY

Who's the expert?

Name: Dr Kausik Kumar Ray - MD

Institution: Imperial College London

Bio:

  • Professor of Public Health, Department of Public Health and Primary Care, School of Public Health, Imperial College London.
  • PI for ORION 1 trial assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. 
  • Has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes. 

Interview Questions
Q1.

Please describe your clinical practice and how many patients you treat.

Added By: joe_mccann
Q2.

What was your reaction to the FOURIER data? 

Added By: joe_mccann
Q3.

Do you think each PCSK9 drug will need specific outcomes results?

Added By: joe_mccann
Q4.

Do the FOURIER results change the "expected" benefits from various LDL lowering changes? 

Added By: joe_mccann
Q5.

How does the inclusion criteria in ORION-1 trial compare to ODYSSEY and FOURIER. Is 130mg/dL better in your opinion for these trials? Were enough patients on optimal statin regimens such as Ezetimibe

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.